It is time for drug makers to embrace continuous manufacturing methods, CDER Director Janet Woodcock and other FDA officials have been emphasizing in recent months. Now the agency is offering additional support to help manufacturers overcome regulatory barriers, real or perceived, and wean themselves from batch processes.
FDA officials are encouraging the pharmaceutical industry to switch from batch to continuous manufacturing, and they’re promising to help with the transition.
The agency’s message is being delivered at conferences by a variety of FDA officials, including Janet Woodcock, director of the...